Clinical trials: 1st-line Treatment
Synovial Sarcoma, Cancer
A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)
To assess if the CMB305 vaccine regimen may help the body's immune system to slow or stop the growth of synovial sarcoma tumor and improve survival.
- Conditions
- Synovial Sarcoma, Cancer, Soft Tissue Sarcoma, Sarcoma
- Trial name
- NCT03520959
- Testing
- LV305, G305
- Where
- 29 sites in United States, Canada
- Volunteers
- 1 people
- Sponsor
- Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Hemophagocytic Lymphohistiocytosis (HLH)
Treatment of Familiar Lymphohistiocytosis
The purpose of this project is to study the number of surviving patients until hematopoietic stem cell transplantation (HSCT) after first line treatment of hemophagocytic lymphohistiocytosis (HLH) by Alemtuzumab
- Trial name
- C-HLH (NCT02472054)
- Testing
- Alemtuzumab, Methyl Prednisolone (MP), Cyclosporin A (CSA)
- Where
- France
- Volunteers
- 29 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Neuroendocrine Carcinoma of Lung, Neuroendocrine Carcinoma of Thymus
CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors
The study involves the enrollment of 34 patients diagnosed with advanced thymic, pulmonary and duodeno-pancreatic well-differentiated high grade neuroendocrine tumors (Ki-67 > 20%).
- Trial name
- LINEAR (NCT07429851)
- Where
- Italy
- Volunteers
- 34 people
- Sponsor
- European Institute of Oncology
Ulcerative Colitis (UC), Acute Severe Ulcerative Colitis
Effectiveness and Safety of Upadacitinib for Acute Severe Ulcerative Colitis
The aim of this retrospective observational study is to investigate and compare the real-world effectiveness and safety of upadacitinib when used as first-line exposure versus rescue exposure in patients with acute severe…
- Conditions
- Ulcerative Colitis (UC), Acute Severe Ulcerative Colitis, Upadacitinib
- Trial name
- NCT07472309
- Testing
- Upadacitinib
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Colorectal Neoplasms, RAS
The Safety and Efficacy of Cetuximab Beta Plus Fruquintinib With or Without Immune Checkpoint Inhibitorrs in First-line Treatment of RAS/BRAF Wild Type Unresectable Metastatic Colorectal Cancer
Colorectal cancer is a malignant tumor ranking among the top four in incidence and the top three in causes of death globally . Chemotherapy combined with anti-EGFR or anti-VEGF monoclonal antibodies is currently the standard…
- Conditions
- Colorectal Neoplasms, RAS, BRAF, Cetuximabβ
- Trial name
- concept (NCT07257653)
- Testing
- Cetuximab β；Fruquintinib；, Cetuximab β；Fruquintinib；anti-PD1 antibody；, Cetuximab β；Fruquintinib；anti-PD1/CTLA4 antibody
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Zhejiang University
Renal Colic
IV NSAI Versus Nebulized Morphine Analgesia for First-line Renal Colic
The aim of the investigators study was to evaluate the feasibility, efficacy and safety of nebulized morphine compared with non-steroidal anti-inflammatory (NSAI)intravenously in the management of renal colic.
- Trial name
- NSAIvsNM (NCT02156596)
- Testing
- IV NSAI, NM, IV Serum Saline
- Where
- Tunisia
- Volunteers
- 100 people
- Sponsor
- University of Monastir
Breast Cancer Stage IV
RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody
This is a retrospective, single-arm real-world study based on the National Anticancer Drug Clinical Application Monitoring Network database.The aim of this study is to evaluate the efficacy and safety of paclitaxel liposome…
- Trial name
- NCT06481553
- Testing
- first line treatment
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Autologous Stem Cell Transplantation
Stem Cell Harvesting Using GCSF Plus Plerxiafor, in First -Line, for Heavily Pre- Treated Pediatric Oncology Patients.
Plerixafor has been intensively used in recent years for harvesting autologous stem cells from lymphoma and myeloma adult patients. Its use is indicated after failure to harvest with GCSF alone.
- Trial name
- GCSF (NCT02006225)
- Testing
- Plerixafor
- Volunteers
- 30 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Macrophage Activation Syndrome
Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome
The present study was a single-center, prospective, non-comparative in which macrophage activation syndrome patients were selected as the main subjects to evaluate the effect and safety of Ruxolitinib and methylprednisolone…
- Trial name
- NCT05137496
- Testing
- Ruxolitinib, methylprednisolone
- Volunteers
- 40 people
- Sponsor
- Beijing Friendship Hospital
Helicobacter Pylori Infection
Bismuth Quadruple Therapy Versus Standard Triple Therapy
The goal of this clinical trial is to compare the standard triple therapy with Bismuth quadruple therapy in children infected with Helicobacter pylori.
- Trial name
- BismoHelP (NCT06143124)
- Testing
- Bismuth Subcitrate
- Where
- Slovenia
- Volunteers
- 216 people
- Sponsor
- University Medical Centre Ljubljana
Breast Cancer
BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer
Some chemotherapies, including docetaxel, are better tolerated and just as effective when giving the dose weekly rather than on an every three week basis.
- Trial name
- BREAST-10 (NCT00540800)
- Testing
- docetaxel, epirubicin, capecitabine
- Where
- 3 sites in Italy
- Volunteers
- 139 people
- Sponsor
- National Cancer Institute, Naples
Breast Cancer
Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
Triple negative breast cancer (TNBC) is a difficult to treat molecular subtype with a poor survival. TNBC can be divided into at least two molecular entities; BRCA-like and non-BRCA-like.
- Trial name
- Triple-B (NCT01898117)
- Testing
- Carbo/cyclo, Carbo/cyclo + atezolizumab, Paclitaxel
- Where
- 49 sites in Netherlands
- Volunteers
- 304 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer
This trial studies the effects on quality of life and on time to second progression of the sequence endocrine therapy-capecitabine versus the sequence capecitabine-endocrine treatment.
- Trial name
- NCT00684216
- Testing
- capecitabine, hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- The Netherlands Cancer Institute
aGVHD
Umbilical Cord Mesenchymal Stem Cells as First-line Treatment for Patients With Acute Graft Versus Host Disease
Allogenic haemopoietic stem cell transplantation (allo-HSCT) is the effective treatment for many hematologic malignancies and some non-malignant diseases.
- Trial name
- NCT05531266
- Testing
- hUC-MSCs, glucocorticoids
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Graft-versus-host Disease
Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II Acute Graft-versus-Host Disease
This study aims to evaluate the efficacy and safety of low-dose corticosteroids combined with ruxolitinib in the treatment of grade II acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell…
- Trial name
- NCT07576010
- Testing
- RUX+Steroids
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Daihong Liu
Breast Cancer
Chemotherapy and Hormone Therapy as First-Line Therapy in Treating Postmenopausal Women With Metastatic or Locally Advanced Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT00403182
- Testing
- chemotherapy, letrozole
- Where
- 9 sites in Germany
- Sponsor
- Technical University of Munich
Carcinoma, Non-Small-Cell Lung
A Multicountry, Multicentre, Non-interventional, Retrospective Study to Determine Real-world Treatment Patterns and Associated Outcomes After First Line Osimertinib in Patients With Advanced and Metastatic NSCLC EGFRm in the GCC Region
A Multicountry, Multicenter, Non-interventional, Retrospective Study to determine Real-world treatment patterns and associated outcomes after FIRST LINE Osimertinib in patients with advanced and Metastatic NSCLC harboring…
- Trial name
- TREASURE (NCT06039683)
- Where
- 7 sites in Kuwait, Qatar and 2 more
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Human Immunodeficiency Virus, HIV
Europe-Africa Research Network for Evaluation of Second-line Therapy
The trial aim is to ascertain what, if anything, needs to be combined with a boosted protease inhibitor (bPI) backbone in second-line therapy in order to maximize the chance of a good clinical outcome following WHO-defined…
- Trial name
- EARNEST (NCT00988039)
- Testing
- Aluvia + 2NRTIs, Aluvia + raltegravir, Aluvia monotherapy
- Where
- 14 sites in Kenya, Malawi and 3 more
- Volunteers
- 1,277 people
- Sponsor
- Justine Boles
Neurogenic Bladder
Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder
The purpose of this study is to investigate the use of Botulinum Toxin A as primary therapy for children with neurogenic bladder due to spina bifida and compare results with standard oral oxybutynin therapy.
- Trial name
- NCT01716624
- Testing
- Oxybutynin, Botulinum Toxin A injection
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
CHD - Congenital Heart Disease
Feasibility of Home Telemonitoring of Infants With Congenital Heart Disease Awaiting Surgery During the First Year of Life
Actually, there is no telemonitoring program that includes newborns or infants with congenital heart disease awaiting cardiac intervention.
- Trial name
- Blue-Line (NCT06998290)
- Testing
- Blue-Line home telemonitoring program
- Where
- 2 sites in France
- Volunteers
- 20 people
- Sponsor
- University Hospital, Bordeaux